NCT06431438View on ClinicalTrials.gov

Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

759

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

November 20, 2023

Study Completion Date

November 20, 2023

Conditions
Chronic Hepatitis B
Interventions
DRUG

TQA3810

TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist

Trial Locations (1)

210008

Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY